公开(公告)号：US20060134646A1

公开(公告)日：2006-06-22

申请号：US11015631

申请日：2004-12-17

申请人： Aftab Ansari ,  M. Gershwin

发明人： Aftab Ansari ,  M. Gershwin

IPC分类号： C12Q1/68 ,  G01N33/53

CPC分类号： G01N33/56988 ,  A61K31/522 ,  A61K31/55 ,  A61K31/7072 ,  A61K35/36 ,  A61K39/12 ,  A61K39/275 ,  C12N2710/24134 ,  G01N2333/16 ,  G01N2800/52 ,  A61K2300/00

摘要： A method for treatment of HIV infection includes administering at least one anti-HIV drug, such as a reverse transcriptase inhibitor, to a patient in need of such treatment and administering an extract from inflammatory tissue inoculated with vaccinia virus to the patient following the administration of the at least one anti-HIV drug. The extract maintains suppressive action on HIV replication, even if the administration of the anti-HIV drug is terminated.

摘要翻译： 一种用于治疗HIV感染的方法包括向需要这种治疗的患者施用至少一种抗HIV药物，例如逆转录酶抑制剂，并且在施用疫苗后向患者施用痘苗病毒接种的炎性组织的提取物 至少一种抗艾滋病毒药物。 提取物维持对HIV复制的抑制作用，即使终止了抗HIV药物的给药。

公开(公告)号：US20060093620A1

公开(公告)日：2006-05-04

申请号：US11304578

申请日：2005-12-16

申请人： Falko-Guenter Falkner ,  Georg Holzer ,  Sogue Coulibaly ,  Josef Mayrhofer

发明人： Falko-Guenter Falkner ,  Georg Holzer ,  Sogue Coulibaly ,  Josef Mayrhofer

IPC分类号： A61K39/12 ,  C12Q1/68

CPC分类号： C12N15/86 ,  A61K39/00 ,  A61K39/12 ,  A61K39/275 ,  A61K2039/525 ,  A61K2039/5256 ,  C07K2319/00 ,  C12N9/1211 ,  C12N2710/24143 ,  C12N2770/24143

摘要： The present invention provides recombinant poxviruses, such as vaccinia virus, that contain an integrated exogenous sequence, such as a foreign gene, encoding a prodrug converting polypeptide that can convert a prodrug to a drug that prevents virus replication or is otherwise toxic to the virus. The recombinant poxviruses can be suitable for use as vaccines. The invention also provides, among other things, methods of inhibiting virus replication, methods of vaccination and methods of treating vaccinated subjects showing signs or otherwise at risk for of vaccination-induced disease.

公开(公告)号：US07025970B2

公开(公告)日：2006-04-11

申请号：US10388234

申请日：2003-03-14

申请人： Falko-Guenter Falkner ,  Georg Holzer ,  Sogue Coulibaly ,  Josef Mayrhofer

发明人： Falko-Guenter Falkner ,  Georg Holzer ,  Sogue Coulibaly ,  Josef Mayrhofer

IPC分类号： A61K39/285 ,  A61K39/42

CPC分类号： C12N15/86 ,  A61K39/00 ,  A61K39/12 ,  A61K39/275 ,  A61K2039/525 ,  A61K2039/5256 ,  C07K2319/00 ,  C12N9/1211 ,  C12N2710/24143 ,  C12N2770/24143

摘要： The present invention provides recombinant poxviruses, such as vaccinia virus, that contain an integrated exogenous sequence, such as a foreign gene, encoding a prodrug converting polypeptide that can convert a prodrug to a drug that prevents virus replication or is otherwise toxic to the virus. The recombinant poxviruses can be suitable for use as vaccines. The invention also provides, among other things, methods of inhibiting virus replication, methods of vaccination and methods of treating vaccinated subjects showing signs or otherwise at risk for of vaccination-induced disease.

公开(公告)号：US07015024B1

公开(公告)日：2006-03-21

申请号：US08470357

申请日：1995-06-06

申请人： Bernard Moss ,  Michael Mackett ,  Geoffrey L. Smith

发明人： Bernard Moss ,  Michael Mackett ,  Geoffrey L. Smith

IPC分类号： C12N7/01 ,  C12N5/10 ,  A61K39/275 ,  A61K39/285

CPC分类号： C12N15/86 ,  A61K39/00 ,  A61K39/12 ,  A61K39/275 ,  A61K39/285 ,  A61K2039/5256 ,  C07K14/005 ,  C12N7/00 ,  C12N9/1033 ,  C12N2710/16622 ,  C12N2710/24122 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2730/10122 ,  C12N2760/20234 ,  Y02A50/403 ,  Y02A50/464 ,  Y02A50/466

摘要： Recombinant poxviruses, such as vaccinia, are provided that comprises a segment comprised of (A) a first DNA sequence encoding a polypeptide that is foreign to poxvirus and (B) a poxvirus transcriptional regulatory sequence, wherein (i) said transcriptional regulatory sequence is adjacent to and exerts transcriptional control over said first DNA sequence and (ii) said segment is positioned within a nonessential genomic region of said recombinant poxvirus. Vaccines, carriers, cells, and media comprising recombinant poxviruses, and methods of immunization with recombinant poxviruses, also are provided.

摘要翻译： 提供重组痘病毒，例如牛痘，其包含由（A）编码痘病毒异源的多肽的第一DNA序列和（B）痘病毒转录调节序列组成的片段，其中（i）所述转录调控序列相邻 对所述第一DNA序列进行转录控制，并且（ii）所述片段位于所述重组痘病毒的非必需基因组区域内。 还提供了疫苗，载体，细胞和包含重组痘病毒的培养基，以及用重组痘病毒免疫的方法。

公开(公告)号：US06752996B2

公开(公告)日：2004-06-22

申请号：US10414609

申请日：2003-04-15

申请人： Stephen A. Johnston ,  Michael J. McGuire

发明人： Stephen A. Johnston ,  Michael J. McGuire

IPC分类号： A61K4500

CPC分类号： C07K14/005 ,  A61K38/162 ,  A61K39/00 ,  A61K39/12 ,  A61K39/275 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55561 ,  C07K19/00 ,  C07K2319/00 ,  C12N2710/24022 ,  C12N2710/24034 ,  C12N2710/24222 ,  C12N2710/24234 ,  C12N2760/16122

摘要： The Parapox B2L virus envelope protein is used as an adjuvant to enhance a subject's response to an administered antigen. Both antibody and cellular immune responses can be modified. B2L protein is particularly useful as an adjuvant for poorly immunogenic tumor vaccines and subunit vaccines, such as those useful for preventing and/or treating flu, tuberculosis, respiratory syncytial virus, anthrax and HIV.

摘要翻译： 使用Parapox B2L病毒包膜蛋白作为佐剂以增强受试者对施用的抗原的反应。 抗体和细胞免疫应答都可以修改。 B2L蛋白特别可用作用于低免疫原性肿瘤疫苗和亚单位疫苗的佐剂，例如可用于预防和/或治疗流感，结核病，呼吸道合胞病毒，炭疽和HIV的那些。

公开(公告)号：US20040054159A1

公开(公告)日：2004-03-18

申请号：US10414759

申请日：2003-04-15

发明人： Stephen A. Johnston ,  Michael J. McGuire

IPC分类号： C07H021/04 ,  A61K039/38 ,  A61K039/245 ,  A61K047/00 ,  C07K014/00 ,  A61K039/00 ,  A61K045/00 ,  C07K017/00 ,  A61K039/12 ,  C07K001/00

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/275 ,  A61K39/39 ,  A61K2039/55516 ,  C12N2710/24222 ,  C12N2710/24234

摘要： The Parapox B2L virus envelope protein is used as an adjuvant to enhance a subject's response to an administered antigen. Both antibody and cellular immune responses can be modified. B2L protein is particularly useful as an adjuvant for poorly immunogenic tumor vaccines and subunit vaccines, such as those useful for preventing and/or treating flu, tuberculosis, respiratory syncytial virus, anthrax and HIV.

摘要翻译： 使用Parapox B2L病毒包膜蛋白作为佐剂以增强受试者对施用的抗原的反应。 抗体和细胞免疫应答都可以修改。 B2L蛋白特别可用作用于低免疫原性肿瘤疫苗和亚单位疫苗的佐剂，例如可用于预防和/或治疗流感，结核病，呼吸道合胞病毒，炭疽和HIV的那些。

公开(公告)号：US06562376B2

公开(公告)日：2003-05-13

申请号：US09800632

申请日：2001-03-07

申请人： Jay W. Hooper ,  Alan L. Schmaljohn ,  Connie S. Schmaljohn

发明人： Jay W. Hooper ,  Alan L. Schmaljohn ,  Connie S. Schmaljohn

IPC分类号： A61K914

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/275 ,  A61K39/285 ,  A61K2039/53 ,  A61K2039/57 ,  C12N2710/24122 ,  C12N2710/24134

摘要： In this application is described a poxvirus naked DNA vaccine which protects animals against poxvirus challenge comprising IMV and EEV nucleic acids from poxvirus. Methods of use of the vaccine and its advantages are described.

公开(公告)号：US06537594B1

公开(公告)日：2003-03-25

申请号：US09535370

申请日：2000-03-24

申请人： Enzo Paoletti ,  James Tartaglia ,  William I. Cox

发明人： Enzo Paoletti ,  James Tartaglia ,  William I. Cox

IPC分类号： A61F200

CPC分类号： C12N15/86 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/145 ,  A61K39/17 ,  A61K39/205 ,  A61K39/275 ,  A61K39/285 ,  A61K2039/5254 ,  A61K2039/5256 ,  C07K14/005 ,  C07K14/33 ,  C07K14/4746 ,  C07K14/525 ,  C07K14/535 ,  C07K14/5406 ,  C07K14/5434 ,  C07K14/55 ,  C07K14/57 ,  C07K14/705 ,  C07K14/70532 ,  C07K14/82 ,  C07K2319/00 ,  C12N7/00 ,  C12N15/00 ,  C12N2710/16122 ,  C12N2710/16222 ,  C12N2710/16622 ,  C12N2710/16722 ,  C12N2710/24022 ,  C12N2710/24043 ,  C12N2710/24122 ,  C12N2710/24143 ,  C12N2730/10122 ,  C12N2740/13022 ,  C12N2740/15022 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2750/14322 ,  C12N2760/12022 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/18122 ,  C12N2760/18422 ,  C12N2760/18722 ,  C12N2760/20022 ,  C12N2760/20122 ,  C12N2760/20134 ,  C12N2770/20022 ,  C12N2770/24022 ,  C12N2770/24122

摘要： Attenuated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least on of: human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IFN&ggr;; IL-4; GNCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.

摘要翻译： 包含编码细胞因子和/或肿瘤相关抗原的DNA的减毒重组病毒以及采用病毒的方法和组合物被公开和要求保护。 重组病毒可以是NYVAC或ALVAC重组病毒。 DNA可编码至少一种：人类肿瘤坏死因子; 核磷蛋白p53，野生型或突变体; 人黑素瘤相关抗原; IL-2; IFNgamma; IL-4; GNCSF; IL-12; B7; erb-B-2和癌胚抗原。 重组病毒及其基因产物可用于癌症治疗。

公开(公告)号：US20020051792A1

公开(公告)日：2002-05-02

申请号：US09303040

申请日：1999-04-30

发明人： BARBARA J. WINSLOW ,  MARK D. COCHRAN

IPC分类号： A61K039/12

CPC分类号： A61K39/275 ,  A61K38/1774 ,  A61K38/208 ,  A61K39/00 ,  A61K39/39 ,  A61K2039/5256 ,  A61K2039/55516 ,  A61K2300/00

摘要： The present invention involves a recombinant virus which comprises at least one foreign nucleic acid inserted within a non-essential region of the viral genome of a virus, wherein each such foreign nucleic acid encodes a protein. The protein which is encoded is selected from the groups consisting of a feline CD28 protein or an immunogenic portion thereof, a feline cD80 protein or an immunogenic portion thereof, a feline CD86 protein or an immunogenic portion thereof, or a feline CTLA-4 protein or an immunogenic portion thereof. The protein is capable of being expressed when the recombinant virus is introduced into an appropiate host. The present invention also involves a recombinant virus further comprising a foreign nucleic acid encoding an immunogen derived from a pathogen. The present invention also comprises recombinant viruses which are capable of enhancing an immune response in a feline. The present invention also comprises recombinant viruses which are capable of suppressing an immune respons in a feline.

摘要翻译： 本发明涉及重组病毒，其包含插入到病毒的病毒基因组的非必需区域内的至少一种外来核酸，其中每个这样的外源核酸编码蛋白质。 编码的蛋白质选自猫科动物CD28蛋白或其免疫原性部分，猫cD80蛋白或其免疫原性部分，猫CD86蛋白或其免疫原性部分或猫CTLA-4蛋白质或 其免疫原性部分。 当将重组病毒引入适当的宿主时，蛋白质能够被表达。 本发明还涉及另外包含编码来自病原体的免疫原的外源核酸的重组病毒。 本发明还包括能够增强猫科动物的免疫应答的重组病毒。 本发明还包括能够抑制猫科动物的免疫反应的重组病毒。

公开(公告)号：US3186908A

公开(公告)日：1965-06-01

申请号：US21729362

申请日：1962-08-16

申请人： PARKE DAVIS & CO

发明人： RIGHTSEL WILTON A ,  POINTE WOODS GROSSE ,  SCHULER EDWARD E

IPC分类号： A61K39/12 ,  A61K39/13 ,  A61K39/165 ,  A61K39/275 ,  A61K39/285

CPC分类号： A61K39/165 ,  A61K39/12 ,  A61K39/13 ,  A61K39/275 ,  A61K39/285 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2710/24134 ,  C12N2760/18434 ,  Y10S514/896

摘要： Antigenic virus materials, especially aqueous vaccines of all types in liquid or in freeze-dried form, are stabilized by incorporating therein at least 0.1% by weight of calcium lactobionate. Desirably 2-10% of lactose may also be incorporated and the vaccines of the invention are stated to retain their antigenicity at higher temperatures (e.g. at -20 DEG C. instead of -60 DEG C. for a measles vaccine) and to be able to withstand repeated freeze/thaw cycles. Other vaccines specifically mentioned are poliomyelitis, infectious hepatitis, yellow fever, mumps, rabies, smallpox and vaccinia vaccines.